We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Donor-Linked Biomarker Predicts Likelihood of Liver Transplant Success

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Image: A healthy human liver. A biomarker linked to the organ donor predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ (Photo courtesy of  Wikimedia Commons)
Image: A healthy human liver. A biomarker linked to the organ donor predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ (Photo courtesy of Wikimedia Commons)
A recent paper identified a biomarker linked to the organ donor that predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ.

Compatibility between donor and recipient depends on the similarity of the HLA (human leukocyte antigen) proteins expressed by both. A measure of this similarity is the HLA evolutionary divergence (HED), a continuous metric that quantifies the peptidic differences between two homologous HLA alleles, reflecting the size of the immunopeptide region resented to T-lymphocytes.

In this recent paper, investigators at Assistance Publique, Hôpitaux de Paris, (France) sought to assess the potential effect of donor or recipient HED on liver transplant rejection.

For this study, they accessed the medical records of 1154 adults and 113 children who had a liver transplant between 2004 and 2018. Liver biopsies were done one, two, five, and 10 years after the transplant and in case of liver dysfunction. Donor-specific anti-HLA antibodies (DSAs) were measured in children at the time of biopsy. The HED was calculated using the physicochemical Grantham distance for class I (HLA-A or HLA-B) and class II (HLA-DRB1 or HLA-DQB1) alleles. Grantham's distance depends on three properties: composition, polarity and molecular volume. According to Grantham's distance, the most similar amino acids are leucine and isoleucine and the most distant are cysteine and tryptophan.

The influence of HED on the incidence of liver lesions was analyzed through the inverse probability weighting approach based on covariate balancing, generalized propensity scores.

Data obtained during the study showed that in adults, class I HED of the donor was associated with acute rejection, chronic rejection, and ductopenia of 50% or more but not with other histologic lesions. In children, class I HED of the donor was also associated with acute rejection independent of the presence of DSAs. There was no effect of either donor class II HED or recipient class I or class II HED on the incidence of liver lesions in adults and children. Thus, HED calculated from the HLA alleles of the donor had a much stronger influence on liver transplant success than HLA compatibility. The higher the HED of a donor of liver graft, the more frequent rejection, and this was completely independent of the HLA compatibility of donors and recipients.

These findings allowed the investigators to conclude, “Class I HED of the donor predicts acute or chronic rejection of liver transplant. This novel and accessible prognostic marker could orientate donor selection and guide immunosuppression.”

The study was published in the August 24, 2021, online edition of the journal Annals of Internal Medicine.

Related Links:
Assistance Publique, Hôpitaux de Paris

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Toxoplasma Rapid Test
Toxo IgG/IgM Rapid Test Kit

Print article

Channels

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.